GlassScriptPhysician profile
Daniel J Musser
NPI 1679912877
$3,755.81
in general payments reported to CMS, 2019-2025
26 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.87 · 2020: $130 · 2021: $937 · 2022: $789 · 2023: $572 · 2024: $840 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,320.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $320.56 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $278.65 | 2022-2025 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.66 | 2024-2025 | Caplyta |
| Optinose US, INC. | $231.66 | 2020-2024 | |
| Lilly USA, LLC | $190.49 | 2022-2025 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $136.21 | 2021 | |
| Genentech USA, INC. | $116.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $111.83 | 2020-2025 | Airsupra |
| Glaxosmithkline, LLC. | $109.82 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Grifols USA, LLC | $106.60 | 2023-2024 | Prolastin-C Liquid |
| Amgen INC. | $94.49 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $71.41 | 2023-2024 | |
| Boston Scientific Corporation | $67.28 | 2022-2023 | |
| Exact Sciences Corporation | $49.46 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.08 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $41.41 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.00 | 2024 | |
| Pfizer INC. | $36.22 | 2024 | |
| Kaleo, INC. | $30.02 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $18.92 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $17.70 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $17.69 | 2023 | Horizant |
| Shield Therapeutics INC | $17.37 | 2025 | |
| Horizon Therapeutics Plc | $13.05 | 2020 | |
| Allegis Pharmaceuticals, LLC | $12.18 | 2023 | Urimar-T Caps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Musser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.